Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) EBITDA: 2016-2024

Historic EBITDA for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Dec 2024 value amounting to -$298.4 million.

  • Crinetics Pharmaceuticals' EBITDA fell 73.62% to -$129.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$422.9 million, marking a year-over-year decrease of 53.79%. This contributed to the annual value of -$298.4 million for FY2024, which is 42.36% down from last year.
  • Latest data reveals that Crinetics Pharmaceuticals reported EBITDA of -$298.4 million as of FY2024, which was down 42.36% from -$209.6 million recorded in FY2023.
  • Over the past 5 years, Crinetics Pharmaceuticals' EBITDA peaked at -$73.9 million during FY2020, and registered a low of -$298.4 million during FY2024.
  • For the 3-year period, Crinetics Pharmaceuticals' EBITDA averaged around -$225.2 million, with its median value being -$209.6 million (2023).
  • Data for Crinetics Pharmaceuticals' EBITDA shows a maximum YoY plummeted of 54.99% (in 2022) over the last 5 years.
  • Over the past 5 years, Crinetics Pharmaceuticals' EBITDA (Yearly) stood at -$73.9 million in 2020, then plummeted by 46.14% to -$108.0 million in 2021, then plummeted by 54.99% to -$167.5 million in 2022, then decreased by 25.17% to -$209.6 million in 2023, then tumbled by 42.36% to -$298.4 million in 2024.